Nls Pharmaceutics LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
League Jinn Sarl and Julien Ruggieri have filed a Schedule 13D, disclosing beneficial ownership of 25.3% of NewcelX Ltd. common shares, primarily acquired through private placements and a merger.
NewcelX Ltd.'s Chief Scientific Officer and Director, Prof. Michel Revel, has increased his beneficial ownership to 20.2% of the company's common shares following a private placement and merger.
NewcelX Ltd.'s Executive Chairman and CEO, Ronen Twito, has filed a Schedule 13D disclosing beneficial ownership of 6.0% of the company's common shares following the merger of NLS Pharmaceutics and Kadimastem.
SCHEDULE 13D: NLS Pharmaceutics Chairman Ronald Hafner Boosts Stake to 13.2% Through Strategic Transactions and Debt Conversions
Ronald Hafner, Chairman of NLS Pharmaceutics Ltd., has significantly increased his beneficial ownership to 13.2% through a series of equity purchases, warrant acquisitions, debt-to-equity conversions, and a put-call agreement.